OPTOMEDNasdaq HelsinkiHealth Information ServicesIFRS · EUR

Optomed Oyj

Optomed is a Finnish health technology company specializing in handheld fundus cameras and screening software solutions. The company integrates its devices with software and AI to revolutionize the diagnosis process of diseases like diabetic retinopathy. Optomed operates globally, with offices in Finland, the USA, and China, and distributes its products in over 60 countries. The company is transitioning from innovation-driven development to large-scale commercial deployment, focusing on integrating its technology into primary healthcare settings.

Ask about the company
Revenue17.1m EUR
+13.7 %y/y
Operating profit (EBIT)-6.0m EUR
−1.4 %y/y
EBIT margin-35.3%
+4.3 ppy/y
Net income-6.6m EUR
−21.8 %y/y
Free cash flow-3.0m EUR
−62.6 %y/y

Fiscal year 2025 · change from previous year

Development 2021–2025

-10-505101520m EUR2021: 15 m EUR2021: EBIT -4.8 m EUR20212022: 15 m EUR2022: EBIT -5.1 m EUR20222023: 15 m EUR2023: EBIT -4.0 m EUR20232024: 15 m EUR2024: EBIT -6.0 m EUR20242025: 17 m EUR2025: EBIT -6.0 m EUR2025TTM 2026: 16 m EURTTM 2026: EBIT -6.1 m EURTTM16-6.1
RevenueOperating profit (EBIT)TTM = last 12 months, not a full fiscal year
Ask Clarifo about Optomed Oyj

Business

Share of revenue
Fundus Cameras50 %

Handheld devices for retinal imaging.

Screening Software30 %

Software solutions for disease screening.

AI Solutions10 %

AI integration for enhanced diagnostic accuracy.

Clinical Solutions10 %

Comprehensive solutions for clinical environments.

Customers

Optomed's customer base primarily includes healthcare providers such as hospitals, clinics, and eye care specialists who require advanced diagnostic tools. The company's products are particularly valuable in primary healthcare settings for early disease detection, especially diabetic retinopathy. Optomed also targets healthcare systems looking to integrate AI-driven solutions for improved diagnostic efficiency. The global reach of Optomed's distribution network allows it to cater to diverse markets, enhancing accessibility to its innovative healthcare solutions.

Healthcare Providers

Hospitals and clinics purchasing diagnostic tools for retinal imaging.

Eye Care Specialists

Specialists using fundus cameras for detailed eye examinations.

Healthcare Systems

Systems integrating AI solutions for enhanced diagnostic processes.

Strategy

Optomed's strategic priorities include expanding its market presence by scaling its commercial operations and integrating its technology into primary healthcare. The company focuses on enhancing the usability and connectivity of its devices, exemplified by the launch of the Optomed Lumo camera. Optomed aims to leverage AI to improve diagnostic accuracy and efficiency, positioning itself as a leader in AI-driven healthcare solutions. The company also seeks to strengthen its global distribution network to increase accessibility to its products.

Commercial ExpansionMedium term

To increase market presence and sales.

AI IntegrationLong term

To improve diagnostic accuracy and efficiency.

Product UsabilityShort term

To enhance user experience and workflow efficiency.

Geography

2025

Optomed operates internationally, with key offices in Finland, the USA, and China. Its products are distributed in over 60 countries, allowing the company to tap into diverse healthcare markets. The manufacturing of Optomed's devices takes place in Thailand, which is strategically important for cost-effective production. The company's presence in major markets like the USA ensures access to advanced healthcare systems and regulatory environments that support AI-driven diagnostics.

Finland96 %
Rest of World3.9 %

Share of the revenue the company reports by geography.

Risks

Optomed faces several risks including geopolitical tensions that could impact its supply chain and sales competitiveness. The quality and safety of its products are crucial for maintaining market position, and any failure in product development could negatively affect the company. Strategic execution risks exist, as successful implementation depends on factors beyond the company's control. Additionally, Optomed must navigate complex regulatory environments across different countries, which could pose legal and compliance challenges.

Sorted by severity
LowMediumHighLowMediumHighImpact →Likelihood →Product Quality1Geopolitical Tensions2Regulatory Compliance3
Impact is the risk’s severity and likelihood how probable it is over the next few years, both assessed from the company’s reports. Numbers match the list.
  1. Product QualityImpact: CriticalLikelihood: Medium

    Essential for maintaining competitive edge.

  2. Geopolitical TensionsImpact: HighLikelihood: Medium

    Could disrupt supply chain and increase costs.

  3. Regulatory ComplianceImpact: HighLikelihood: Medium

    Complex international regulations pose challenges.

Ask Clarifo about Optomed Oyj

Accounting

Judgemental items
Revenue Recognition

Critical for international sales and contract variations.

Inventory Valuation

Impacts financial position due to global operations.

R&D Expenses

Essential for innovation and product development.

Similar listed companies

Publicly listed companies with a comparable business focus.

Orion Oyj

ORNBV · Drug Manufacturers - General

Terveystalo Oyj

TTALO · Medical Care Facilities

Revenio Group Oyj

REG1V · Medical Devices

Advanced Biomed Inc.

ADVB · Services-Medical Laboratories

Sitowise Group Oyj

SITOWS · Engineering & Construction

Omnicell, Inc

OMCL · Electronic Computers

Last updated: 24/09/2026

Optomed Oyj (OPTOMED) Revenue, Earnings & Financials 2025 – Clarifo